API-1 is a novel small molecule inhibitor that has gained research attention in recent years as a possible anti-cancer therapeutic, and, while evidence shows reduced pAKTSer473, to our knowledge it is unclear if both pAKTThr308 and Ser473 are reduced with API-1 treatment [31,42,43,44]. Here, BIRC2 is linked to cancer.